Conjugate Vaccine Market Report 2026

The conjugate vaccine market size has grown rapidly in recent years. It will grow from $21.26 billion in 2025 to $23.84 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to government-led immunization initiatives, high prevalence of bacterial infections, support from global health organizations, proven efficacy of conjugate vaccines, increasing pediatric population.

The conjugate vaccine market size is expected to see rapid growth in the next few years. It will grow to $38.54 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to rising demand for combination vaccines, expansion of adult vaccination programs, increased funding for vaccine r&d, growing focus on antimicrobial resistance, improving cold chain infrastructure. Major trends in the forecast period include expansion of pediatric immunization programs, rising adoption of multivalent conjugate vaccines, increasing focus on long-term immunogenicity, growth in public-private vaccine partnerships, advancements in carrier protein technologies.

The increasing incidence of infectious diseases is anticipated to drive the expansion of the conjugate vaccine market. Infectious diseases are conditions caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, which can spread directly or indirectly between individuals, from animals to humans, or through environmental exposure. Conjugate vaccines are essential in preventing infectious diseases caused by specific bacteria, particularly among high-risk groups such as infants and young children. For example, according to the Centers for Disease Control and Prevention, a US-based government agency, tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, representing a rise of 1,295 cases. During the same period, the incidence rate grew from 2.5 per 100,000 people in 2022 to 2.9 in 2023. Consequently, the growing burden of infectious diseases is contributing to the growth of the conjugate vaccine market.

Key companies operating in the conjugate vaccine market are concentrating on the development of next-generation conjugate vaccines to deliver broader protection against multiple pneumococcal serotypes and reduce disease burden among vulnerable populations. These next-generation conjugate vaccines link bacterial polysaccharides to carrier proteins to enhance immune responses, especially in infants and immunocompromised individuals, providing improved protection, longer-lasting immunity, and greater effectiveness compared with conventional vaccines. For instance, in August 2025, Pfizer Ltd. launched its next-generation 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., PCV20, for adults in India. This launch strengthened the company’s conjugate vaccine portfolio by offering expanded protection against pneumococcal disease and supporting improved public health outcomes.

In December 2024, Sanofi expanded its collaboration with SK bioscience to advance the development of next-generation pneumococcal conjugate vaccines (PCV21). Through this partnership, Sanofi aims to accelerate the phase 3 clinical development program for PCV21 and enhance its vaccine portfolio by leveraging SK bioscience’s expertise in vaccine research, development, and manufacturing.

Major companies operating in the conjugate vaccine market are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus.

North America was the largest region in the global conjugate vaccine market in 2025. The regions covered in the conjugate vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the conjugate vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the conjugate vaccine market by increasing costs associated with imported raw materials, carrier proteins, and specialized manufacturing equipment used in vaccine conjugation. These cost pressures affect bacterial conjugate vaccine segments and multivalent products more significantly, with emerging regions in Asia-Pacific and Africa facing supply delays due to reliance on imports. However, tariffs are also encouraging local manufacturing, technology transfer agreements, and regional self-sufficiency in vaccine production, supporting long-term market resilience.

The conjugate vaccine market research report is one of a series of new reports that provides conjugate vaccine market statistics, including conjugate vaccine industry global market size, regional shares, competitors with a conjugate vaccine market share, detailed conjugate vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the conjugate vaccine industry. This conjugate vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Conjugate vaccines, also referred to as immunogen conjugates, are advanced modulators of the immune system that are widely used to provide protection against invading pathogens or to stimulate the production of specific antibodies against a target molecule. The conjugation process strengthens the immune response and enables more effective recognition of the pathogen by the immune system.

The primary types of conjugate vaccines include monovalent conjugate vaccines and multivalent conjugate vaccines. Monovalent conjugate vaccines contain a single conjugated antigen, usually aimed at a specific pathogen or strain, and are used to prevent infections caused by bacteria with a polysaccharide capsule, such as Streptococcus pneumoniae, Haemophilus influenzae type B, and Neisseria meningitidis. These vaccines are developed against various bacterial and viral pathogens to treat diseases including pneumococcal, influenza, meningococcal, and typhoid infections, for both pediatric and adult patients, and are used in hospitals, clinics, homecare settings, and other healthcare environments.

The conjugate vaccine market consists of sales of diphtheria, tetanus, and pertussis (DTaP) conjugate vaccine, haemophilus influenza type b (Hib) conjugate vaccine, and E. coli conjugate vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.